HeartBeam Raises $10M from 12.5M-Share Offering to Fuel ECG Technology Commercialization
HeartBeam closed a public offering of 12.5 million shares, raising $10 million gross before expenses. The company will use proceeds to commercialize its FDA-cleared 12-lead synthesized ECG, advance extended-wear patch and heart attack detection technologies, expand AI capabilities and fund general corporate purposes.
1. Offering Details
HeartBeam completed an underwritten public offering of 12.5 million shares on April 16, 2026, generating gross proceeds of $10 million before expenses. Key stakeholders including ClearCardio, company leadership and institutional investors supported the offering.
2. Use of Proceeds
Proceeds will fund commercialization of the company’s FDA-cleared 12-lead synthesized ECG system, further development of its extended-wear patch and heart attack detection technologies, expansion of AI capabilities and general corporate purposes.
3. Technology Background
HeartBeam’s 3D ECG platform synthesizes standard 12-lead ECG signals from three non-coplanar directions without cables. The technology received FDA clearance for arrhythmia assessment in December 2024 and 12-lead synthesis software in December 2025, backed by over 20 issued patents.